Literature DB >> 12840122

Management of stable angina.

A Jain1, V Wadehra, A D Timmis.   

Abstract

Ischaemic heart disease may present as a wide variety of clinical entities including unstable or stable angina pectoris, acute myocardial infarction, and occasionally heart failure. Chronic stable angina is a common condition and results in a considerable burden for both the individual and society. The goals in management are (i) treatment of other conditions that may worsen angina; (ii) modification of risk factors and treatment with medications for coronary artery disease to improve outcome; and (iii) effective relief of anginal symptoms. There are limitations to the methods available to risk-stratify patients, and the optimal treatment strategy remains unclear. The benefits of lifestyle modification cannot be over-emphasised, and appropriate attention to modifiable risk factors is paramount. The mortality benefit of lipid lowering treatment and antiplatelet therapy is well proved. However the evidence base for anti-ischaemic therapy is less rigorous, being based mainly on extrapolations from studies of acute coronary syndromes. Angioplasty has been shown to be more effective in relief of symptoms than medical therapy alone, but provides no mortality benefit. Coronary artery bypass surgery, however, has been shown to reduce mortality in patients with severe proximal coronary disease when compared with medical management alone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12840122      PMCID: PMC1742719          DOI: 10.1136/pmj.79.932.332

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  47 in total

Review 1.  Diabetic heart disease: clinical considerations.

Authors:  A D Timmis
Journal:  Heart       Date:  2001-04       Impact factor: 5.994

Review 2.  Myocardial perfusion imaging.

Authors:  R J Gibbons
Journal:  Heart       Date:  2000-03       Impact factor: 5.994

Review 3.  Diagnostic and prognostic use of stress echocardiography in stable patients.

Authors:  S C Smart; K B Sagar
Journal:  Echocardiography       Date:  2000-07       Impact factor: 1.724

Review 4.  Stress echocardiography for assessing myocardial ischaemia and viable myocardium.

Authors:  R Senior; A Kenny; P Nihoyannopoulos
Journal:  Heart       Date:  1997-08       Impact factor: 5.994

5.  Primary prevention of coronary heart disease in women through diet and lifestyle.

Authors:  M J Stampfer; F B Hu; J E Manson; E B Rimm; W C Willett
Journal:  N Engl J Med       Date:  2000-07-06       Impact factor: 91.245

6.  Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials.

Authors:  H C Bucher; P Hengstler; C Schindler; G H Guyatt
Journal:  BMJ       Date:  2000-07-08

Review 7.  Guidelines for management of hypertension: report of the third working party of the British Hypertension Society.

Authors:  L Ramsay; B Williams; G Johnston; G MacGregor; L Poston; J Potter; N Poulter; G Russell
Journal:  J Hum Hypertens       Date:  1999-09       Impact factor: 3.012

8.  Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.

Authors:  P S Sanmuganathan; P Ghahramani; P R Jackson; E J Wallis; L E Ramsay
Journal:  Heart       Date:  2001-03       Impact factor: 5.994

9.  Effects of cardiac rehabilitation and exercise training in obese patients with coronary artery disease.

Authors:  C J Lavie; R V Milani
Journal:  Chest       Date:  1996-01       Impact factor: 9.410

Review 10.  Non-invasive coronary artery imaging with electron beam computed tomography and magnetic resonance imaging.

Authors:  P J de Feyter; K Nieman; P van Ooijen; M Oudkerk
Journal:  Heart       Date:  2000-10       Impact factor: 5.994

View more
  1 in total

1.  Sanqi panax notoginseng injection for angina pectoris.

Authors:  Xiaochen Yang; Xingjiang Xiong; Jie Wang
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-16       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.